Cognitive symptoms in schizophrenia: Diagnosis and pharmacotherapy;Kognitive symptomatik bei schizophrener erkrankung: Diagnostik und pharmakotherapie

Journal fur Neurologie, Neurochirurgie und Psychiatrie

Volumn 3, Issue 4, 2002, Pages 17-22

  Hilger, Eva ^a   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical antipsychotics; Cognitive dysfunction; Neuropsychological tests; Schizophrenia

Indexed keywords

AMISULPRIDE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; CLINICAL PRACTICE; COGNITIVE DEFECT; DRUG EFFECT; NEUROTRANSMISSION; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOSOCIAL DISORDER; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0036909691     PISSN: 16081587     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Zec RF. Neuropsychology of schizophrenia according to Kraepelin: Disorders of volition and executive functioning. Eur Arch Psychiatry Clin Neurosci 1995; 245: 216-23.
2. nd, Alliger RJ, Yuh WT, Cohen G, Ziebell S. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry 1990; 47: 35-44.
3. Andreasen NC, Paradiso S, O'Leary DS. "Cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr Bull 1998; 24: 203-18.
4. Cannon TD, Marco E. Structural brain abnormalities as indicators of vulnerability to schizophrenia. Schizophr Bull 1994; 20: 89-102.
5. Volz HP, Hager F. The use of functional imaging methods for the study of cognition disorders. Fortschr Neurol Psychiatr 1999; Suppl 2: 58-63.
6. nd, Flaum M, Kirchner P, Cohen G, O'Leary DS. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992; 49: 943-58.
7. Barch DM, Carter CS, Braver TS, Sabb FW, MacDonald A. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 2001; 58: 280-8.
8. Green MF. Schizophrenia from a Neuro-Cognitive Perspective. Allyn and Bacon, Boston, 1998.
9. Cannon TD, Zorrilla LE, Shtasel D, Gur RE, Gur RC, Marco EJ, Moberg P, Price RA. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry 1994; 51: 651-61.
10. Laurent A, Moreaud O, Bosson JL, Naegele B, Boucharlat J, Saoud M, Dalery J, Dámato T. Neuropsychological functioning among non-psychotic siblings and parents of schizophrenic patients. Psychiatry Res 1999; 87: 147-57.
11. Tollefson GD. Cognitive function in schizophrenic patients. J Clin Psychiatry 1996; 57: 31-9.
12. Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull 1999; 25: 309-18.
13. King DJ, Green JF. Medication and cognitive functioning in schizophrenia. In: Pantels C, Nelson HE, Barnes TRE (eds). Schizophrenia. A Neuropsychological Perspective. Wiley, Chichester, 1996; 419-44.
14. Mortimer AM. Cognitive function in schizophrenia - Do neuroleptics make a difference? Pharmacol Biochem Behav 1997; 6: 789-95.
15. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989; 98: 478-86.
16. Kasper S, Möller HJ (eds). Die Rolle der Kognition in der Therapie Schizophrener Störungen. Deutscher Universitätsverlag, Wiesbaden, 2000.
17. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176-84.
18. Gourovitch ML, Goldberg TE. Cognitive deficits in schizophrenia: Attention, executive functions, memory, and language processing. In: Pantelis C, Nelson HE, Barnes TR (eds). Schizophrenia: A Neuro-Psychological Perspective. Wiley, Chichester, 1996; 71-86.
19. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 1984; 10: 160-203.
20. Broadbent D. Perception and Communication. Pergamon, Oxford, 1958.
21. Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 1992; 49: 975-82.
22. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: A meta-analysis. Am J Psychiatry 1999; 156: 1358-66.
23. Saykin JA, Gur RC, Gur RE, Mozley PM, Mozley LH, Resnick SM, Kester DB, Stafiniak P. Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Arch Gen Psychiatry 1991; 48: 618-24.
24. Aylward E, Walker E, Bettes B. Intelligence in schizophrenia: Meta-analysis of research. Schizophr Bull 1984; 10: 430-59.
25. Goldberg TE, Hyde TM, Kleinman JE, Weinberger DR. Course of schizophrenia: Neuropsychological evidence for a static encephalopathy. Schizophr Bull 1993; 19: 797-804.
26. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1998; 153: 321-30.
27. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 1997; 25: 21-31.
28. Ito M, Kanno M, Mori Y, Niwa S. Attention deficits assessed by Continuous Performance Test and Span of Apprehension Test in Japanese schizophrenic patients. Schizophr Res 1997; 23: 205-11.
29. Stroop JR. Farbe-Wort-Interferenz-Test FWIT. Hogrefe, Göttingen, 1985.
30. Tewes U. Hamburg-Wechsler-Intelligenztest für Erwachsene - Revision 1991 (HAWIE-R). Huber, Bern, Stuttgart, Toronto, 1991.
31. Reitan R. Validity of the trail-making test as an indicator of organic brain damage. Perceptual and Motor Skills 1958; 8: 271-6.
32. Hawkins KA. Memory deficits in patients with schizophrenia: Preliminary data from the Wechsler Memory Scale-Third Edition support earlier findings. J Psychiatry Neurosci 1999; 24: 341-7.
33. Brand N, Jolles J. Learning and retrieval rate of words presented auditorily and visually. J Gen Psychol 1985; 8: 271-6.
34. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 32: 632-7.
35. Grant DA, Berg EA. Wisconsin Card Sorting Test (WCST). Psychological Assessment Resources. Odessa, Florida, 1993.
36. Kasper S. How much do novel antipsychotics benefit the patients? Int Clin Psychopharmacol 1998; 13: 71-7.
37. Hilger E, Kasper S. Atypical neuroleptics: New approaches to drug therapy of schizophrenic disorders. Wien Klin Wochenschr 2000; 112: 1031-8.
38. Blin O. A comparative review of new antipsychotics. Can J Psychiatry 1999; 44: 235-44.
39. Purdon SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 1999; 35 (Suppl): 51-60.
40. Sharma T, Mockler D. The cognitive efficacy of atypical anti-psychotics in schizophrenia. J Clin Psychopharmacol 1998; 18: 2-19.
41. Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: The place of atypical antipsychotics in treatment. J Clin Psychiatry 1999; 60 (Suppl 23): 25-8.
42. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical anti-psychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6 (Suppl 2): 13-20.
43. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 1999; 25: 201-22.
44. Weiser M, Shneider-Beeri M, Nakash N, Brill N, Bawnik O, Reiss S, Hocherman S, Davidson M. Improvement in cognition associated with novel antipsychotic drugs: A direct drug effect or reduction of EPS? Schizophr Res 2000; 46: 81-9.
45. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233-55.
46. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162: 43-8.
47. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702-12.
48. McGurk C. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999; 60: 24-9.
49. Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: A prospective study. J Clin Psychiatry 1998; 59: 521-7.
50. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154: 799-804.
51. Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, McGurk SR, Marder SR, Mintz J. Risperidone versus haloperidol on secondary memory: Can newer medications aid learning? Schizophr Bull 1999; 25: 223-32.
52. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study. Acta Psychiatr Scand 1997; 95: 40-3.
53. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: A longitudinal study. Schizophr Res 2001; 48: 17-28.
54. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000; 57: 249-58.
55. Strip E, Luisser I, Babal M, Fabian JL. Seroquel and cognitive improvement in patients with schizophrenia. Biol Psychiatry 1996; 40: 434-35.
56. Fleming K, Thyrum P, Yeh C, Vargo DL, Potkin SG. Cognitive improvements in psychotic subjects treated with "Seroquel" (quetiapine fumarate): An exploratory study. J Clin Psychopharmacol 2001; 21: 527-9.
57. Sax KW, Strakowski SM, Keck PE Jr. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 1998; 33: 151-5.
58. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26: 137-49.
59. Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double-blind study. Pharmacopsychiatry 1997; 30: 35-42.
60. Serper MR, Chou JNY. Novel neuroleptics improve attentional functioning in schizophrenic patients: Ziprasidone and aripiprazole. CNS Spectrums 1997; 2: 56-9.
61. Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, Patat A, O'Hanlon JF. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol 1999; 19: 209-21.
62. Patat A, Rosenzweig P, Miget N, Allain H, Gandon JM. Effects of 50 mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects. Fundam Clin Pharmacol 1999; 13: 582-94.
63. Sachs G. Psychologische Behandlungsstrategien von kognitiven Funktionsstörungen bei schizophrenen Psychosen. In: Möller HJ, Kasper S (eds). Die Rolle der Kognition in der Therapie Schizophrenet Störungen. Deutscher Universitätsverlag, Wiesbaden, 2000; 173-87.
64. Roder V, Brenner HD, Kienzle N, Hodel B. Integriertes Psychologisches Therapieprogramm für Schizophrene Patienten (IPT). 3. Überarbeitete und Ergänzte Auflage. Beltz, München, Weinheim, 1995.
65. Green MF. Cognitive remediation in schizophrenia: Is it time yet? Am J Psychiatry 1993; 150: 178-87.
66. Hermanutz M, Gestrich J. Computer-assisted training in schizophrenics: A comparative study. Eur Arch Psychiatry Clin Neurosci 1991; 240: 282-7.